The Technical Analyst
Arvinas Inc [ARVN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Arvinas Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-2.58% $34.00
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2 322.49 mill |
| EPS: | -6.62 |
| P/E: | -5.14 |
| Earnings Date: | May 03, 2024 |
| SharesOutstanding: | 68.31 mill |
| Avg Daily Volume: | 0.766 mill |
| RATING 2024-04-23 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.14 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.87x |
| Company: PE -5.14 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-17.57 (-151.66%) $-51.57 |
| Date: 2024-04-23 |
| Expected Trading Range (DAY) |
|---|
|
$ 31.97 - 36.04 ( +/- 5.99%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-18 | Berkowitz Noah | Buy | 93 879 | Stock Option (right to buy) |
| 2024-03-18 | Berkowitz Noah | Buy | 63 452 | Common Stock |
| 2024-03-18 | Berkowitz Noah | Buy | 0 | |
| 2024-02-29 | Teel Randy | Sell | 0 | Common Stock |
| 2024-02-29 | Teel Randy | Sell | 0 | Common Stock |
| INSIDER POWER |
|---|
| 45.61 |
| Last 95 transactions |
| Buy: 1 590 588 | Sell: 490 115 |
Forecast:
16:00 - $34.00
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $34.00
Forecast 2: 16:00 - $34.00
Forecast 3: 16:00 - $34.00
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $34.00 (-2.58% ) |
| Volume | 0.523 mill |
| Avg. Vol. | 0.766 mill |
| % of Avg. Vol | 68.22 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ARVN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $48.12 | N/A | Active |
|---|
ARVN
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Latest Press Releases
2024-04-11 07:00:00 - Press Release
Arvinas Enters Into A Transaction With Novartis, Including A Global License Agreement For The Development And Commercialization Of Protac® Androgen Receptor (ar) Protein Degrader Arv-766 For The Treatment Of Prostate Cancer
– arvinas to receive a $150 million upfront payment for the license of arv-766 and the sale of arvinas' preclinical ar-v7 program, with the potential under the license agreement for up to $1.01 billion in development, regulatory, and commercial milestones, as well as tiered royalties –
2024-03-18 16:40:00 - Press Release
Arvinas Appoints Noah Berkowitz, M.d., Ph.d., As Chief Medical Officer
- awards dr. berkowitz an inducement grant in accordance with nasdaq listing rule 5635(c)(4) - - awards dr. berkowitz an inducement grant in accordance with nasdaq listing rule 5635(c)(4) -
2024-03-04 07:00:00 - Press Release
Arvinas To Participate In Upcoming Investor Conferences
New haven, conn., march 04, 2024 (globe newswire) -- arvinas, inc. (nasdaq: arvn), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor conferences:
2024-02-27 07:00:00 - Press Release
Arvinas Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Corporate Update
– enrollment continues globally in multiple clinical studies of vepdegestrant (arv-471) in er+/her2- metastatic breast cancer, including the veritac-2 phase 3 trial in the second-line setting and the study lead-in for the veritac-3 phase 3 trial in the first-line setting –
2024-02-20 16:05:00 - Press Release
Arvinas Announces Chief Financial Officer Transition
- sean cassidy leaving arvinas as of february 29, 2024 - - randy teel, ph.d. to assume the role of interim chief financial officer - new haven, conn.
Latest News
2024-04-11 11:31:00 - Invezz
Arvinas inks over $1.0 billion deal with Novartis
Arvinas Inc (NASDAQ: ARVN) is in the green at writing after announcing a deal worth over $1.0 billion with Novartis (SWX: NOVN). Details of Arvinas – Novartis agreement Novartis will pay $150 million to the pharmaceutical company up front.
2024-04-09 09:51:24 - Zacks Investment Research
Is Arvinas (ARVN) Stock a Solid Choice Right Now?
Arvinas (ARVN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
2024-03-04 07:00:00 - GlobeNewsWire
Arvinas to Participate in Upcoming Investor Conferences
NEW HAVEN, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor conferences:
2024-02-28 09:31:15 - Zacks Investment Research
Is a Surprise Coming for Arvinas (ARVN) This Earnings Season?
Arvinas (ARVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
2024-02-27 09:31:04 - Zacks Investment Research
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
Arvinas, Inc. (ARVN) came out with a quarterly loss of $2.53 per share versus the Zacks Consensus Estimate of a loss of $1.33. This compares to loss of $1.56 per share a year ago.
2024-02-23 10:56:07 - Zacks Investment Research
Wall Street Analysts See a 30.21% Upside in Arvinas, Inc. (ARVN): Can the Stock Really Move This High?
The consensus price target hints at a 30.2% upside potential for Arvinas, Inc. (ARVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2024-02-21 13:01:13 - Zacks Investment Research
What Makes Arvinas, Inc. (ARVN) a Strong Momentum Stock: Buy Now?
Does Arvinas, Inc. (ARVN) have what it takes to be a top stock pick for momentum investors? Let's find out.
2024-02-06 10:56:11 - Zacks Investment Research
Wall Street Analysts Think Arvinas, Inc. (ARVN) Could Surge 26.67%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in Arvinas, Inc. (ARVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2024-02-02 04:01:03 - Zacks Investment Research
Arvinas, Inc. (ARVN) Soars 10.0%: Is Further Upside Left in the Stock?
Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
2024-02-01 16:30:00 - GlobeNewsWire
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
NEW HAVEN, Conn., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ron Peck, M.D., Chief Medical Officer, and Randy Teel, Ph.D., Senior Vice President, Corporate and Business Development will participate in a fireside chat at the 6th Annual Guggenheim Biotechnology Conference on Wednesday, February 7 at 10:30 a.m. ET in New York.